Arsanis, Inc. today announced that the first cohort has been initiated in its Phase 1 clinical trial of ASN100, a novel combination of two monoclonal antibodies that target the pathogen Staphylococcus aureus. The study is being conducted in Vienna, Austria, and will examine the safety, tolerability, and pharmacokinetics of ASN100 in healthy volunteers.

View Document